A Phase 1b Dose Escalation/Dose Expansion Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma
Latest Information Update: 21 Nov 2022
At a glance
- Drugs Icapamespib (Primary)
- Indications Astrocytoma; Glioblastoma; Glioma; Gliosarcoma
- Focus Adverse reactions; Pharmacokinetics
- Acronyms Glio
- Sponsors Samus Therapeutics
- 04 Nov 2022 Status changed from recruiting to discontinued.
- 05 Jan 2022 According to a Samus Therapeutics media release, the first patient was dosed in the study.
- 05 Jan 2022 Status changed from not yet recruiting to recruiting, according to a Samus Therapeutics media release.